Development of a lethal intranasal exposure model of ebola virus in the cynomolgus macaque

Viruses

Volumn 9, Issue 11, 2017, Pages

  Alfson, Kendra J ^a   Avena, Laura E ^a,b   Worwa, Gabriella ^a   Carrion, Ricardo ^a   Griffiths, Anthony ^a,b  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Animal model; Ebola virus; Intranasal

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE; NUCLEOPROTEIN; PENTOBARBITAL; PYRUVATE SODIUM; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BLOOD CLOTTING; EBOLA HEMORRHAGIC FEVER; EXPOSURE; FILOVIRUS; HEMATOLOGY; HISTOPATHOLOGY; LETHAL DOSE; LIVER; LUNG; LYMPH NODE; MACACA FASCICULARIS; NONHUMAN; PRECLINICAL STUDY; RESPIRATORY DISTRESS; UREA NITROGEN BLOOD LEVEL; VIRUS GENOME; ANIMAL; BLOOD; DISEASE MODEL; EBOLAVIRUS; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; PATHOGENICITY; VIROLOGY;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MACACA FASCICULARIS;

EID: 85033474015     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v9110319     Document Type: Article

References (37)

1. Baize, S.; Pannetier, D.; Oestereich, L.; Rieger, T.; Koivogui, L.; Magassouba, N.; Soropogui, B.; Sow, M. S.; Keïta, S.; de Clerck, H.; et al. Emergence of zaire ebola virus disease in guinea. N. Engl. J. Med. 2014, 371, 1418–1425.
2. Marsh, G. A.; Haining, J.; Robinson, R.; Foord, A.; Yamada, M.; Barr, J. A.; Payne, J.; White, J.; Yu, M.; Bingham, J.; et al. Ebola reston virus infection of pigs: Clinical significance and transmission Potential. J. Infect. Dis. 2011, 204, S804–S809.
3. Martina, B. E. E.; Osterhaus, A. D. M. E. “Filoviruses”: A real pandemic threat? EMBO Mol. Med. 2009, 1, 10–18.
4. Swanepoel, R.; Leman, P. A.; Burt, F. J.; Zachariades, N. A.; Braack, L. E.; Ksiazek, T. G.; Rollin, P. E.; Zaki, S. R.; Peters, C. J. Experimental inoculation of plants and animals with ebola virus. Emerg. Infect. Dis. 1996, 2, 321–325.
5. Gronvall, G. K.; Trent, D.; Borio, L.; Brey, R.; Nagao, L. The FDA animal efficacy rule and biodefense. Nat. Biotechnol. 2007, 25, 1084–1087.
6. Crawford, L. M. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final Rule. Fed. Regist. 2002, 67, 37988–37998.
7. Judson, S.; Prescott, J.; Munster, V. Understanding ebola virus transmission. Viruses 2015, 7, 511–512.
8. Institute of Medicine; National Research Council. Research Priorities to Inform Public Health and Medical Practice for Ebola Virus Disease: Workshop in Brief; The National Academies Press: Washington, DC, USA, 2014.
9. Bray, M.; Davis, K.; Geisbert, T.; Schmaljohn, C.; Huggins, J. A mouse model for evaluation of prophylaxis and therapy of ebola hemorrhagic fever. J. Infect. Dis. 1999, 179 (Suppl. 1), S248–S258.
10. Connolly, B. M.; Steele, K. E.; Davis, K. J.; Geisbert, T. W.; Kell, W. M.; Jaax, N. K.; Jahrling, P. B. Pathogenesis of experimental ebola virus infection in guinea pigs. J. Infect. Dis. 1999, 179 (Suppl. 1), S203–S217.
11. Kozak, R.; He, S.; Kroeker, A.; de La Vega, M. -A.; Audet, J.; Wong, G.; Urfano, C.; Antonation, K.; Embury-Hyatt, C.; Kobinger, G. P.; et al. Ferrets infected with bundibugyo virus or ebola virus recapitulate important aspects of human filovirus disease. J. Virol. 2016, 90, 9209–9223.
12. Nakayama, E.; Saijo, M. Animal models for ebola and marburg virus infections. Front. Microbiol. 2013, 4, 267.
13. Feldmann, H.; Sanchez, A.; Geisbert, T. W. Filoviridae: Marburg and ebola viruses. Fields Virol. 2013, 1, 923–956.
14. Osterholm, M. T.; Moore, K. A.; Kelley, N. S.; Brosseau, L. M.; Wong, G.; Murphy, F. A.; Peters, C. J.; LeDuc, J. W.; Russell, P. K.; van Herp, M.; et al. Transmission of ebola viruses: What we know and what we do not know. MBio 2015, 6, e00137.
15. Sullivan, N. J.; Martin, J. E.; Graham, B. S.; Nabel, G. J. Correlates of protective immunity for ebola vaccines: Implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 2009, 7, 393–400.
16. Dowell, S. F.; Mukunu, R.; Ksiazek, T. G.; Khan, A. S.; Rollin, P. E.; Peters, C. J. Transmission of Ebola hemorrhagic fever: A study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J. Infect. Dis. 1999, 179 (Suppl. 1), S87–S91.
17. Klenk, H. -D.; Feldmann, H. Ebola and marburg viruses; Garland Science, Horizon Bioscience: Wymondham, UK, 2004.
18. Jaax, N. K.; Davis, K. J.; Geisbert, T. J.; Vogel, P.; Jaax, G. P.; Topper, M.; Jahrling, P. B. Lethal experimental infection of rhesus monkeys with ebola-zaire (mayinga) virus by the oral and conjunctival route of exposure. Arch. Pathol. Lab. Med. 1996, 120, 140–155.
19. Mire, C. E.; Geisbert, J. B.; Agans, K. N.; Deer, D. J.; Fenton, K. A.; Geisbert, T. W. Oral and conjunctival exposure of nonhuman primates to low doses of ebola makona virus. J. Infect. Dis. 2016, 214, S263–S267.
20. Johnson, E.; Jaax, N.; White, J.; Jahrling, P. Lethal experimental infections of rhesus monkeys by aerosolized ebola virus. Int. J. Exp. Pathol 1995, 76, 227–236.
21. Geisbert, T. W.; Daddario-Dicaprio, K. M.; Geisbert, J. B.; Reed, D. S.; Feldmann, F.; Grolla, A.; Ströher, U.; Fritz, E. A.; Hensley, L. E.; Jones, S. M.; et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with ebola and marburg viruses. Vaccine 2008, 26, 6894–6900.
22. Gralton, J.; Tovey, E.; McLaws, M. -L.; Rawlinson, W. D. The role of particle size in aerosolised pathogen transmission: A review. J. Infect. 2011, 62, 1–13.
23. National Research Council, Division on Earth and Life Studies, Institute for Laboratory Animal Research, Committee for the Update of the Guide for the Care and Use of Laboratory Animals. National research council guide for the care and use of laboratory animals, 8th ed.; The National Academies Press: Washington, DC, USA, 2010.
24. Trombley, A. R.; Wachter, L.; Garrison, J.; Buckley-Beason, V. A.; Jahrling, J.; Hensley, L. E.; Schoepp, R. J.; Norwood, D. A.; Goba, A.; Fair, J. N.; et al. Comprehensive panel of real-time TaqMan™ polymerase Chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and new world hantaviruses. Am. J. Trop. Med. Hyg. 2010, 82, 954–960.
25. Alfson, K. J.; Avena, L. E.; Beadles, M. W.; Staples, H.; Nunneley, J. W.; Ticer, A.; Dick, E. J.; Owston, M. A.; Reed, C.; Patterson, J. L.; et al. Particle-to-PFU ratio of ebola virus influences disease course and survival in cynomolgus macaques. J. Virol. 2015, 89, 6773–6781.
26. Alfson, K. J.; Worwa, G.; Carrion, R.; Griffiths, A. Determination and therapeutic exploitation of ebola virus spontaneous mutation frequency. J. Virol. 2016, 90, 2345–2355.
27. Hirschberg, R.; Ward, L. A.; Kilgore, N.; Kurnat, R.; Schiltz, H.; Albrecht, M. T.; Christopher, G. W.; Nuzum, E. Challenges, progress, and opportunities: Proceedings of the filovirus medical countermeasures workshop. Viruses 2014, 6, 2673–2697.
28. Shurtleff, A.; Biggins, J.; Keeney, A.; Zumbrun, E.; Bloomfield, H.; Kuehne, A.; Audet, J.; Alfson, K.; Griffiths, A.; Olinger, G.; et al. Standardization of the filovirus plaque assay for use in preclinical studies. Viruses 2012, 4, 3511–3530.
29. Bausch, D. G.; Towner, J. S.; Dowell, S. F.; Kaducu, F.; Lukwiya, M.; Sanchez, A.; Nichol, S. T.; Ksiazek, T. G.; Rollin, P. E. Assessment of the risk of ebola virus transmission from bodily fluids and fomites. J. Infect. Dis. 2007, 196 (Suppl. 2), S142–S147.
30. Pond, K.; Hooper, L.; Edmunds, K.; Hunter, P. Presence and persistence of ebola or marburg virus in patients and survivors: A Rapid systematic review. PLoS Negl. Trop. Dis. 2016, 10, e0004475.
31. Schnittler, H. J.; Feldmann, H. Marburg and ebola hemorrhagic fevers: Does the Primary course of infection depend on the accessibility of organ-specific macrophages? Clin. Infect. Dis. 1998, 27, 404–406.
32. Stroher, U.; West, E.; Bugany, H.; Klenk, H. D.; Schnittler, H. J.; Feldmann, H. Infection and activation of monocytes by marburg and ebola viruses. J. Virol. 2001, 75, 11025–11033.
33. Wong, G.; Qiu, X.; de La Vega, M. -A.; Fernando, L.; Wei, H.; Bello, A.; Fausther-Bovendo, H.; Audet, J.; Kroeker, A.; Kozak, R.; et al. Pathogenicity comparison between the Kikwit and Makona Ebola virus variants in rhesus macaques. J. Infect. Dis. 2016, 214, S281–S289.
34. Kortepeter, M. G.; Bausch, D. G.; Bray, M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J. Infect. Dis. 2011, 204 (Suppl. 3), S810–S816.
35. Bah, E. I.; Lamah, M. -C.; Fletcher, T.; Jacob, S. T.; Brett-Major, D. M.; Sall, A. A.; Shindo, N.; Fischer, W. A.; Lamontagne, F.; Saliou, S. M.; et al. Clinical presentation of patients with ebola virus disease in conakry, guinea. N. Engl. J. Med. 2015, 372, 40–47.
36. Roels, T. H.; Bloom, A. S.; Buffington, J.; Muhungu, G. L.; Mac Kenzie, W. R.; Khan, A. S.; Ndambi, R.; Noah, D. L.; Rolka, H. R.; Peters, C. J.; et al. Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: Risk Factors for patients without a reported exposure. J. Infect. Dis. 1999, 179, S92–S97.
37. Kekulé, A. S. Learning from Ebola virus: How to prevent future epidemics. Viruses 2015, 7, 3789–3797.